Filing Flows

Filing Flows › Companies › Haemonetics › Cash flow

Haemonetics cash flow, quarter by quarter

Latest: Q2 FY27 · from the cash-flow statements filed with the SEC

Free cash flow$113M in Q2 FY27 · $298M over twelve months

Operating cash flow$128M
Capital spending−$14.8M
Free cash flow+$113M
Cash / net income2.8×
Cash conversion cycle217 days

Analysis

In Q2 FY27, Haemonetics generated $128M of operating cash flow and spent $14.8M on capital projects, leaving free cash flow of $113M.

Over the twelve months to Sep 26, 2026, operating cash flow was $345M; the largest uses were other investing ($118M), buybacks ($100M), net borrowing (+) / repaid (−) ($100M); besides operations, cash came from asset & business sales ($1.8M); the cash balance fell by $35.7M.

Operating cash flow was $128M against net income of $46.3M — 2.8× profit, cash ran ahead of reported earnings. The largest differences: payables +$53.6M, depreciation & amortization +$27.8M, stock-based pay +$10.2M.

Its cash conversion cycle was 217 days (receivables 56 + inventory 203 − payables 43).

Free cash flow

Haemonetics: free cash flow by quarterHaemonetics: free cash flow by quarter$35.2MQ3 FY25$101MQ4 FY25$13.6MQ1 FY26$106MQ2 FY26$87.2MQ3 FY26$53.3MQ4 FY26$44.4MQ1 FY27$113MQ2 FY27
Operating cash flow less capital spending.
Haemonetics: operating cash flow against capital spendingHaemonetics: operating cash flow against capital spendingOperating cash flowCapital spending$43.8M$8.5MQ3 FY25$117M$15.6MQ4 FY25$17.4M$3.8MQ1 FY26$111M$5.0MQ2 FY26$93.6M$6.3MQ3 FY26$70.9M$17.7MQ4 FY26$52.3M$7.9MQ1 FY27$128M$14.8MQ2 FY27
Latest (Q2 FY27): Operating cash flow $128M, Capital spending $14.8M.

Capital allocation, year by year

Haemonetics: where the cash came from (up) and went (down), by fiscal yearHaemonetics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingAcquisitionsBuybacksFY22: Operating cash flow $172MFY22: Net borrowing −$17.5MFY22: Shares issued $2.3MFY22: Asset sales $12.7MFY22: Capital spending −$96.5MFY22: Acquisitions −$2.5M$187MFY22FY23: Operating cash flow $273MFY23: Net borrowing $270MFY23: Shares issued $2.6MFY23: Asset sales $2.5MFY23: Capital spending −$191MFY23: Acquisitions −$2.9MFY23: Buybacks −$75.0M$549MFY23FY24: Operating cash flow $182MFY24: Net borrowing $37.8MFY24: Shares issued $1.6MFY24: Asset sales $3.3MFY24: Capital spending −$38.1MFY24: Acquisitions −$244M$224MFY24FY25: Operating cash flow $182MFY25: Net borrowing $195MFY25: Asset sales $66.5MFY25: Capital spending −$39.3MFY25: Acquisitions −$151MFY25: Buybacks −$225M$444MFY25FY26: Operating cash flow $293MFY26: Asset sales $1.4MFY26: Capital spending −$32.8MFY26: Acquisitions −$60.2MFY26: Buybacks −$175M$295MFY26
Over these 5 years operating cash flow totalled $1.1B; the largest uses were buybacks ($475M) and acquisitions ($460M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$261M
Debt$1.1B
Net debt$876M
Due within a year$7.9M

Haemonetics funds itself: free cash flow was $298M over the last twelve months, and $261M of cash and investments stands against $1.1B of debt ($7.9M due within a year, 33.1× covered by cash).

Haemonetics: debt maturities by year (FY26)Haemonetics: debt maturities by year (FY26)$7.9MYear 1$12.6MYear 2$18.8MYear 3$1.2BYear 4$77KYear 5$401KAfter year 5
Principal due in each year as disclosed in the annual report, against $261M of cash and investments now.

Where the cash came from and went

Haemonetics: sources (+) and uses (−) of cash, Q2 FY27Haemonetics: sources (+) and uses (−) of cash, Q2 FY27Operating cash flow$128MNet borrowing (+) / repaid (−)−$51.6MCash drawn (+) / kept (−)−$37.3MOther financing−$17.6MCapital spending−$14.8MOther investing−$10.1MShares issued$2.0MExchange rates$1.1MAsset & business sales$576KTaxes on employees’ shares−$388K
Haemonetics: sources (+) and uses (−) of cash, TTM to Q2 FY27Haemonetics: sources (+) and uses (−) of cash, TTM to Q2 FY27Operating cash flow$345MOther investing−$118MBuybacks−$100MNet borrowing (+) / repaid (−)−$100MCapital spending−$46.7MCash drawn (+) / kept (−)$35.7MOther financing−$14.5MTaxes on employees’ shares−$4.1MAsset & business sales$1.8MExchange rates$563K

From profit to cash

Haemonetics: net income to operating cash flow, Q2 FY27Haemonetics: net income to operating cash flow, Q2 FY27Net income$46.3MDepreciation & amortization$27.8MStock-based pay$10.2MDeferred taxes$2.6MReceivables−$8.4MInventory$2.0MPayables$53.6MOther operating capital−$5.5MOperating cash flow$128M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q2 FY275620343217
Q1 FY275820436227
Q4 FY265419331216
Q3 FY265421937236
Q2 FY265723937259
Q1 FY265725640273
Q4 FY255724043254
Q3 FY255621839234

Every quarter

QuarterOperating cash flowCapital spendingAcquisitionsBuybacksNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 FY27$128M−$14.8M——−$51.6M$2.0M−$37.3M$113M
Q1 FY27$52.3M−$7.9M——−$51.6M$426K$22.1M$44.4M
Q4 FY26$70.9M−$17.7M−$60.2M−$100M——$118M$53.3M
Q3 FY26$93.6M−$6.3M———$1.1M−$66.9M$87.2M
Q2 FY26$111M−$5.0M——−$1.6M$63K−$3.5M$106M
Q1 FY26$17.4M−$3.8M——−$1.6M$462K$13.9M$13.6M
Q4 FY25$117M−$15.6M—−$150M−$1.6M—$14.1M$101M
Q3 FY25$43.8M−$8.5M——−$1.6M$505K−$21.6M$35.2M

Haemonetics: income statement and cash flow

Haemonetics, Q2 FY27: revenue $358M (+9% year over year), operating margin 21.0%. The chart follows the revenue to costs, profit and cash.

Haemonetics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.